Home › High Blood Pressure in Pregnancy › NCT06915792
PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy
Postpartum Evaluation of Antihypertensive Cessation and Efficacy (PEACE): A Randomized Controlled Trial Comparing Oral Labetalol and Oral Extended-Release Nifedipine for Managing Postpartum Hypertension
Who can join
Ages 18 to 64 · Women
Full eligibility criteria
Inclusion criteria: Age ≥18 years Delivery at study institution at ≥28 weeks gestation Postpartum SBP \> 150 and/or DBP \> 100 OR 2 or more SBP \> 140 and/or DBP \> 90 within a 24-hour period Require initiation of an oral antihypertensive medication during postpartum hospital stay or within 7 days of discharge Treating obstetric team amenable to starting either study medication Exclusion criteria: Treated with oral antihypertensive medications prior to delivery Known allergies or contraindications to nifedipine or labetalol History of moderate persistent to severe asthma, chronic obstructive pulmonary disease, heart failure, or greater than first-degree atrioventricular heart block Unable to provide written informed consent in English
About the study
This randomized controlled trial compares two common medications, labetalol and extended-release nifedipine, to determine which is more effective at managing postpartum high blood pressure. We hypothesize that extended-release nifedipine will better control blood pressure and reduce the need for continued medication beyond six weeks postpartum. The study will enroll 110 postpartum participants, randomly assigning them to one of the two medications, with remote blood pressure monitoring to evaluate treatment effectiveness and inform postpartum hypertension management.
What is being tested
- Labetalol (drug)
- Nifedipine (drug)
Sponsor: University of California, Los Angeles · Participants: 110 · Started: Jun 1, 2025
Contact the study team
- Tina A Nguyen, MD · Phone: 310-794-7274
- Sonia S Raghuram, MS · Phone: 408-896-8704
Official record on ClinicalTrials.gov — NCT06915792
Locations in the U.S.
| California | UCLA Ronald Reagan, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.